WAVEMAN · COMPANY

SGP · Spyglass Pharma, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

SGP

Name: SpyGlass Pharma, Inc. (SGP) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

SpyGlass Pharma, Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001778922

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

40 funds added or opened last quarter

below 66% of Medical Devices

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

$1.4M repurchased, FY to 2025-12-31

below 86% of Medical Devices

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

40 funds added or opened positions in the latest 13F quarter, of 53 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +7.1%

+7.1%12M

INSIDER BUY13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 40 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for SpyGlass Pharma, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

RA Capital Healthcare Fund LP

Director

BUY

2026-02-09

248,034.0

$4.0M

RA Capital Healthcare Fund LP

Director

BUY

2026-02-09

3,441,966.0

$55.1M

Behbahani Ali

Director

BUY

2026-02-09

937,500.0

$15.0M

Florence Anthony A. Jr.

—

BUY

2026-02-09

937,500.0

$15.0M

BASKETT FOREST

—

BUY

2026-02-09

937,500.0

$15.0M

17 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 12 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

RA CAPITAL MANAGEMENT, L.P.

8,021,117.0 sh

$178.6M

NEA Management Company, LLC

7,392,301.0 sh

$164.6M

Sands Capital Alternatives, LLC

2,500,012.0 sh

$55.7M

SAMSARA BIOCAPITAL, LLC

2,109,953.0 sh

$47.0M

BlackRock, Inc.

711,712.0 sh

$15.8M

5%+ owners

13D = intent to influence · 13G = passive

RA Capital Management, L.P.

ACTIVIST 13D · 2026-02-17

24.1%

Peter Kolchinsky

ACTIVIST 13D · 2026-02-17

24.1%

Rajeev Shah

ACTIVIST 13D · 2026-02-17

24.1%

RA Capital Healthcare Fund, L.P.

ACTIVIST 13D · 2026-02-17

17.9%

RA Capital Nexus Fund III, L.P.

ACTIVIST 13D · 2026-02-17

6.2%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

JPMorgan Small Cap Growth Fund

$7.8M POSITION · AS OF 2026-03-31

0.4%

Franklin Biotechnology Discovery Fund

$2.5M POSITION · AS OF 2026-04-30

0.2%

JPMorgan Small Cap Blend Fund

$2.5M POSITION · AS OF 2026-03-31

0.2%

Multi-Manager Small Cap Equity Strategies Fund

$1.2M POSITION · AS OF 2026-02-28

0.1%

T. Rowe Price Health Sciences Fund, Inc.

$7.5M POSITION · AS OF 2026-03-31

0.1%

EQ/T.Rowe Price Health Sciences Portfolio

$109.2K POSITION · AS OF 2026-03-31

0.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 6 registered trials, 5 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

1 ACTIVE

Phase 3

2 ACTIVE

Not applicable

1 ACTIVE

Multi-phase

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12
OPERATING INCOME	$-41.4M	$-27.1M
NET INCOME	$-39.9M	$-29.2M
EPS (DILUTED)	-17.98	-16.31
OPERATING CASH FLOW	$-32.7M	$-22.0M
CASH	$96.4M	$16.3M
BUYBACKS	$1.4M	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE